USPTO Examiner CHANDRA GYAN - Art Unit 1674

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19079771PROTEIN-ENCLOSING POLYMERIC MICELLEMarch 2025February 2026Allow1110NoNo
19067426SELF-ASSEMBLING NANOPARTICLESFebruary 2025January 2026Allow1111YesNo
19062335MULTI-DOSE PEN OF TIRZEPATIDEFebruary 2025December 2025Allow911YesNo
19041480PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHYJanuary 2025August 2025Allow610YesNo
18979068METHODS FOR TREATING ALZHEIMER'S DISEASE USING SEMAGLUTIDEDecember 2024September 2025Allow1010YesNo
18967259COMPOSITIONS AND METHODS FOR TREATING DIABETESDecember 2024June 2025Allow721NoNo
18870747HYDROLYZED COLLAGEN FOR USE IN REDUCING BLOOD GLUCOSEDecember 2024January 2026Allow1311YesNo
18929081COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERSOctober 2024September 2025Allow1120YesNo
18907424VASOPRESSIN PREMIX SYSTEMS AND USES THEREOFOctober 2024July 2025Allow1011NoNo
18889097Insulin DerivativeSeptember 2024October 2025Abandon1311YesNo
18807825APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOFAugust 2024February 2025Allow610NoNo
18720291IL-4 DERIVED PEPTIDES FOR USE IN THE TREATMENT OF OBESITYJune 2024April 2025Allow1010YesNo
18634496FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASESApril 2024August 2025Allow1621YesNo
18628440THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22April 2024August 2024Allow410NoNo
18444463COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS AND USES THEREOFFebruary 2024December 2024Allow1011YesNo
18573779METHODS OF USING AND COMPOSITIONS INCLUDING AN INCRETIN ANALOGDecember 2023August 2025Allow2010NoNo
18572577SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOFDecember 2023October 2025Allow2211YesNo
18510553ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTORNovember 2023December 2025Allow2511NoNo
18499523ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITISNovember 2023October 2025Allow2310NoNo
18384511PRODRUGS AND USES THEREOFOctober 2023February 2026Abandon2711NoNo
18477276Compositions and Methods for Peptide ProductionSeptember 2023November 2025Allow2610NoNo
18449876BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERSAugust 2023September 2025Abandon2510NoNo
18230086THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICEAugust 2023July 2025Abandon2410NoNo
18357666TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETESJuly 2023November 2025Allow2810NoNo
18354452METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITIONJuly 2023January 2026Allow3020NoNo
18221206SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOFJuly 2023October 2024Allow1511YesNo
18345775THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22June 2023March 2026Abandon3301NoNo
18345832THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22June 2023July 2025Allow2410YesNo
18341404METHOD OF REDUCING GLUCOSE INTOLERANCE OR INSULIN RESISTANCE IN A PATIENT IN NEED THEREOFJune 2023June 2025Allow2410NoNo
18331197LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOFJune 2023April 2025Allow2221NoNo
18331318Lyophilized FormulationJune 2023April 2024Allow1011NoNo
18206963STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOFJune 2023January 2026Allow3211NoNo
18329358METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALINGJune 2023January 2026Allow3111NoNo
18199817GATA3 INHIBITORS FOR TREATING INSULIN RESISTANCEMay 2023June 2025Allow2510YesNo
18319010Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a DrugMay 2023July 2025Abandon2610NoNo
18318492METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEXMay 2023March 2025Allow2210NoNo
18196813PREPARATION COMPRISING EXANATIDE FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACTMay 2023June 2025Abandon2510NoNo
18304074NOVEL METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF INTERMEDIATEApril 2023August 2025Allow2811YesNo
18136236METHOD OF DELIVERING GONADOTROPIN RELEASING HORMONE OR AN ANALOGUE THEREOF INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICEApril 2023April 2025Abandon2410NoNo
18300354METHODS OF REDUCING NEUROINFLAMMATIONApril 2023January 2026Allow3410NoNo
18028747CLEC2 FUSION PROTEIN AND USES THEREOFMarch 2023February 2026Allow3510YesNo
18122991RECONSTITUTABLE TEVERELIX-TFA COMPOSITIONMarch 2023July 2025Allow2821NoNo
18186098APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOFMarch 2023October 2025Allow3111NoNo
18181852NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEXMarch 2023February 2025Allow2310NoNo
18021712CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPYFebruary 2023February 2026Allow3611NoNo
18087345ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECTDecember 2022April 2025Allow2810NoNo
18087273SHORT CHAIN CERAMIDE-BASED LIPIDS AND USES THEREOFDecember 2022April 2025Allow2810NoNo
18077742USE OF ULTRARAPID ACTING INSULINDecember 2022February 2025Allow2710NoNo
18061182FIBROBLAST GROWTH FACTOR 1 (FGF1) MUTANT PROTEINS THAT SELECTIVELY ACTIVATE FGFR1B TO REDUCE BLOOD GLUCOSEDecember 2022March 2025Abandon2710NoNo
17927304DUAL-AGONIST COMPOUND FOR BOTH GLP-1 AND GIP RECEPTORS AND APPLICATION THEREOFNovember 2022December 2025Allow3710NoNo
17988271Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acidNovember 2022February 2026Allow3921NoNo
17997363Treating Cancer with a Conjugate Comprising an IL-2 MoietyOctober 2022May 2025Allow3111NoNo
18049445ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTIONOctober 2022March 2025Abandon2801NoNo
17930144USE OF GP73 INHIBITOR IN PREPARATION OF MEDICINE FOR TREATING DIABETESSeptember 2022March 2026Abandon4201NoNo
17929209Targeting gamma-delta T Cells in Obesity and CachexiaSeptember 2022March 2025Abandon3010NoNo
17895638INSULIN-TRANSFERRIN FUSION PROTEIN AND ITS PRODRUG, PROINSULIN-TRANSFERRIN, FOR OVERCOMING INSULIN RESISTANCEAugust 2022April 2025Allow3220NoNo
17869948METHODS FOR PROGNOSING AND PREVENTING METASTATIC LIVER DISEASEJuly 2022April 2025Abandon3301NoNo
17813383COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DIABETES AND RELATED DISORDERSJuly 2022November 2024Allow2810NoNo
17863322METHODS FOR DELIVERING ETANERCEPT PREPARATIONS INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICEJuly 2022December 2024Abandon2910NoNo
17758089Insulin DerivativeJune 2022November 2025Allow4121YesNo
17848974COMPOSITIONS AND METHODS FOR TREATING OBESITY AND HYPERPHAGIAJune 2022October 2025Allow3921YesNo
17785786IL2 MUTEINSJune 2022December 2025Allow4211NoNo
17836644ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOFJune 2022December 2024Allow3110YesNo
17836707ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOFJune 2022January 2025Allow3110YesNo
17781530Cyclooxygenase-2 Inhibition for the Treatment of SAA-high AsthmaJune 2022March 2026Abandon4510NoNo
17747723PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINEMay 2022January 2025Allow3210NoNo
17741126Long-Acting Therapeutic Fusion ProteinsMay 2022March 2025Abandon3410NoNo
17724406BIOMARKERS OF FAST PROGRESSION OF CHRONIC KIDNEY DISEASEApril 2022September 2024Allow2901NoNo
17721112METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURYApril 2022March 2025Abandon3510NoNo
17695343PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULINMarch 2022March 2025Abandon3620NoNo
17692238INSULIN CONTAINING PHARMACEUTICAL COMPOSITIONSMarch 2022November 2024Abandon3201NoNo
17634685INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLSFebruary 2022December 2025Allow4611YesNo
17667223A METHOD FOR TREATING DIABETESFebruary 2022November 2024Allow3421NoNo
17588377METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATIONJanuary 2022January 2025Allow3610NoNo
17586872Methods of Treatment Using G-CSF Protein ComplexJanuary 2022September 2024Allow3110NoNo
17562435RAPID-ACTING INSULIN ANALOGUES OF ENHANCED STABILITYDecember 2021January 2025Allow3710NoNo
17549770PHARMACEUTICAL COMPOSITION COMPRISING FRATAXIN FUSION PROTEIN AND METHODS OF USE THEREOFDecember 2021April 2025Allow4031YesNo
17615595HLA TUMOR ANTIGEN PEPTIDES OF CLASS I AND II FOR TREATING MAMMARY/BREAST CARCINOMASDecember 2021November 2025Allow5411YesNo
17534291METHODS OF INCREASING PROGRANULIN LEVELS USING ANTI-SORTILIN ANTIBODIESNovember 2021February 2025Abandon3810NoNo
17534270METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURYNovember 2021January 2025Abandon3710NoNo
17611478FORMULATIONS OF TERLIPRESSINNovember 2021September 2024Allow3410NoNo
17519305ACTRIIB LIGAND TRAP COMPOSITIONS AND USES THEREOFNovember 2021August 2024Allow3421NoNo
17507441STEM CELL RICH PLASMA COMPOSITIONS AND USES THEREOF FOR TREATING AGING SUBJECTSOctober 2021September 2024Allow3511NoNo
17499296Method and Compounds for Treating Diabetes and Associated Metabolic DiseasesOctober 2021September 2024Allow3551YesNo
17461748PHOTORESPONSIVE LIPOSOME, COMPLEX, MEASUREMENT SYSTEM, AND MEASUREMENT METHODAugust 2021August 2025Allow4811NoNo
17443737METHOD FOR SCREENING OF UNPLEASANT ODOR MASKING AGENTSJuly 2021December 2024Allow4010NoNo
17378184COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC HEART DISEASEJuly 2021February 2024Abandon3120NoNo
17332578NUCLEIC ACID MOLECULES ENCODING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)May 2021August 2023Allow2610YesNo
17327498GLUCOSE RESPONSIVE INSULINSMay 2021September 2024Allow4021NoNo
17320118ENGINEERED CD25 POLYPEPTIDES AND USES THEREOFMay 2021June 2025Allow4921YesNo
17292701COMBINATION THERAPIES FOR MULTIPLE MYELOMAMay 2021March 2025Abandon4611NoNo
17315168APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOFMay 2021January 2024Allow3311YesNo
17289898Combination Therapy Method of Treating Myeloproliferative Neoplasms with a Diphtheria Toxin-Human Interleukin-3 Conjugate in Combination with Other AgentsApril 2021March 2025Allow4711NoNo
17237650ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITISApril 2021August 2023Allow2730NoNo
17286445SPHINGOSINE KINASE 1 AND FUSION PROTEIN COMPRISING THE SAME AND USE THEREOFApril 2021December 2024Abandon4411NoNo
17224068LYOPHILIZED MESENCHYMAL STEM CELL DERIVED SECRETOME AND USES THEREOFApril 2021August 2024Allow4121NoNo
17151045METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)January 2021March 2024Allow3820YesNo
17256326ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USESDecember 2020November 2024Allow4711YesNo
17254004NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOFDecember 2020February 2025Allow5011NoNo
17118915METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONSDecember 2020April 2025Allow5221YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANDRA, GYAN.

Strategic Value of Filing an Appeal

Total Appeal Filings
20
Allowed After Appeal Filing
8
(40.0%)
Not Allowed After Appeal Filing
12
(60.0%)
Filing Benefit Percentile
65.0%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHANDRA, GYAN - Prosecution Strategy Guide

Executive Summary

Examiner CHANDRA, GYAN works in Art Unit 1674 and has examined 281 patent applications in our dataset. With an allowance rate of 96.8%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner CHANDRA, GYAN's allowance rate of 96.8% places them in the 87% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHANDRA, GYAN receive 1.88 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHANDRA, GYAN is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +3.0% benefit to allowance rate for applications examined by CHANDRA, GYAN. This interview benefit is in the 24% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 34.9% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 58.1% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 78.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 39.5% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 39.5% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.